COLLEGIUM PHARMACEUTICAL, INC (COLL)
Data as of , from SEC Form 4 filings.
See up to 3 months of COLL. The 7-day demo opens the 1M and 3M ranges and puts COLL on your watchlist.
Start 7-day demoLatest COLL insider trades
About COLLEGIUM PHARMACEUTICAL, INC (COLL)
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
- STOUGHTON, MA
- 423
- 2015
- Nasdaq
https://www.collegiumpharma.comSEC filings for COLL on EDGAR
COLL Form 4 activity by transaction type, last 90 days
No Form 4 activity for COLL in the last 90 days.
COLL insider transactions (Form 4)
6338 Form 4 filings on record, the earliest from Nov 14, 2024, newest first. Filing history page 1 of 2.
| Traded | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Gino Santini | Option exercise | Stock Option (Right to Purchase) | 8,700 | $0.00 | - | |
| Gino Santini | Option exercise | Common Stock | 8,700 | $16.49 | $143K | |
| John Gordon Freund | Open-market sale | Common Stock | 20 | $34.05 | $681 | |
| Nancy Lurker | Grant or award | Common Stock | 8,741 | $0.00 | - | |
| Carlos V. Paya | Grant or award | Common Stock | 8,741 | $0.00 | - | |
| John Gordon Freund | Option exercise | Common Stock | 8,700 | $16.49 | $143K | |
| John Gordon Freund | Open-market sale | Common Stock | 4,127 | $34.54 | $143K | |
| John Gordon Freund | Grant or award | Common Stock | 8,741 | $0.00 | - | |
| John Gordon Freund | Option exercise | Stock Option (Right to Purchase) | 8,700 | $0.00 | - | |
| Garen G. Bohlin | Grant or award | Common Stock | 8,741 | $0.00 | - | |
| Donovan Michael Glancy | Grant or award | Common Stock | 17,482 | $0.00 | - | |
| Rita J. Balice-Gordon | Grant or award | Common Stock | 8,741 | $0.00 | - | |
| Gino Santini | Grant or award | Common Stock | 8,741 | $0.00 | - | |
| Nancy Lurker | Open-market sale | Common Stock | 4,500 | $35.97 footnote F1 | $162K | |
| ||||||
| Garen G. Bohlin | Option exercise | Common Stock | 8,700 | $16.49 | $143K | |
| Garen G. Bohlin | Open-market sale | Common Stock | 8,700 | $37.18 footnote F1 | $323K | |
| Garen G. Bohlin | Option exercise | Stock Option (Right to Purchase) | 8,700 | $0.00 | - | |
| ||||||
| David Dieter - Officer | Tax withholding / forfeiture | Common Stock | 8,840 footnote F1 | $35.72 | $316K | |
| ||||||
| David Dieter - Officer | Open-market sale | Common Stock | 13,976 | $34.92 footnote F2 | $488K | |
| ||||||
| David Dieter - Officer | Open-market sale | Common Stock | 6,224 | $36.65 | $228K | |
 Scott Dreyer - Officer | Open-market sale | Common Stock | 3,559 | $40.99 footnote F3 | $146K | |
| Scott Dreyer - Officer | Open-market sale | Common Stock | 46,417 | $40.36 footnote F2 | $1.87M | |
| ||||||
| David Dieter - Officer | Grant or award | Common Stock | 22,194 footnote F1 | $0.00 | - | |
| David Dieter - Officer | Grant or award | Common Stock | 9,005 footnote F3 | $0.00 | - | |
| David Dieter - Officer | Tax withholding / forfeiture | Common Stock | 2,781 footnote F4 | $46.75 | $130K | |
| ||||||
| Vikram Karnani - Officer | Grant or award | Common Stock | 79,264 footnote F1 | $0.00 | - | |
| Vikram Karnani - Officer | Grant or award | Common Stock | 32,531 footnote F3 | $0.00 | - | |
| Vikram Karnani - Officer | Tax withholding / forfeiture | Common Stock | 11,296 footnote F4 | $46.75 | $528K | |
| ||||||
| Thomas B. Smith - Officer | Grant or award | Common Stock | 14,268 footnote F1 | $0.00 | - | |
| Thomas B. Smith - Officer | Grant or award | Common Stock | 22,774 footnote F3 | $0.00 | - | |
| Thomas B. Smith - Officer | Tax withholding / forfeiture | Common Stock | 5,897 footnote F4 | $46.75 | $276K | |
| Thomas B. Smith - Officer | Tax withholding / forfeiture | Common Stock | 11,538 footnote F5 | $46.75 | $539K | |
| ||||||
| Colleen Tupper - Officer | Grant or award | Common Stock | 26,421 footnote F1 | $0.00 | - | |
| Colleen Tupper - Officer | Grant or award | Common Stock | 32,734 footnote F2 | $0.00 | - | |
| Colleen Tupper - Officer | Tax withholding / forfeiture | Common Stock | 11,861 footnote F3 | $46.75 | $555K | |
| Colleen Tupper - Officer | Tax withholding / forfeiture | Common Stock | 26,679 footnote F4 | $46.75 | $1.25M | |
| ||||||
| Scott Dreyer - Officer | Grant or award | Common Stock | 19,023 footnote F1 | $0.00 | - | |
| Scott Dreyer - Officer | Grant or award | Common Stock | 30,702 footnote F2 | $0.00 | - | |
| Scott Dreyer - Officer | Tax withholding / forfeiture | Common Stock | 9,977 footnote F3 | $46.75 | $466K | |
| Scott Dreyer - Officer | Tax withholding / forfeiture | Common Stock | 21,615 footnote F4 | $46.75 | $1.01M | |
| ||||||
| Vikram Karnani - Officer | Tax withholding / forfeiture | Common Stock | 8,983 footnote F1 | $47.35 | $425K | |
| ||||||
| John A. Fallon | Option exercise | Stock Option (Right to Purchase) | 15,000 | $0.00 | - | |
| John A. Fallon | Option exercise | Stock Option (Right to Purchase) | 19,853 | $0.00 | - | |
| John A. Fallon | Option exercise | Common Stock | 15,000 | $16.49 | $247K | |
| John A. Fallon | Option exercise | Common Stock | 19,853 | $9.33 | $185K | |
| John A. Fallon | Open-market sale | Common Stock | 34,853 | $47.21 footnote F1 | $1.65M | |
| ||||||
| Colleen Tupper - Officer | Open-market sale | Common Stock | 25,142 | $40.38 footnote F2 | $1.02M | |
| Colleen Tupper - Officer | Open-market sale | Common Stock | 4,858 | $41.28 footnote F3 | $201K | |
| ||||||
| Thomas B. Smith - Officer | Open-market sale | Common Stock | 17,478 | $38.42 | $672K | |
| Scott Dreyer - Officer | Option exercise | Common Stock | 16,389 | $21.34 | $350K | |
| Scott Dreyer - Officer | Open-market sale | Common Stock | 16,389 | $38.21 | $626K | |
| Scott Dreyer - Officer | Option exercise | Stock Option (Right to Purchase) | 16,389 | $0.00 | - | |
| Gino Santini - Director | Option exercise | Common Stock | 15,000 | $13.45 | $202K | |
| Gino Santini - Director | Open-market sale | Common Stock | 5,405 | $37.19 | $201K | |
| Gino Santini - Director | Option exercise | Stock Option (Right to Purchase) | 15,000 | $0.00 | - | |
| Scott Dreyer - Officer | Option exercise | Common Stock | 4,861 | $21.34 | $104K | |
| Scott Dreyer - Officer | Open-market sale | Common Stock | 4,861 | $38.03 | $185K | |
| Scott Dreyer - Officer | Option exercise | Stock Option (Right to Purchase) | 4,861 | $0.00 | - | |
| Rubric Capital Management LP - 10% Owner | Open-market sale | Common Stock, par value $0.001 per share | 25,000 | $37.85 | $946K | |
| John Gordon Freund - Director | Open-market sale | Common Stock | 11,659 | $34.36 | $401K | |
| John Gordon Freund - Director | Option exercise | Common Stock | 15,000 | $13.45 | $202K | |
| John Gordon Freund - Director | Open-market sale | Common Stock | 6,601 | $30.62 | $202K | |
| John Gordon Freund - Director | Option exercise | Stock Option (Right to Purchase) | 15,000 | $0.00 | - | |
Item 1.02
Item 8.01
Item 2.02, 7.01
Item 9.01
Recent COLL Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Scott Dreyer | Former Officer | 27,419 | $603K | View on EDGAR | |
| - | - | - |
COLL insider trading FAQ
What is the latest insider trade for COLL?
COLLEGIUM PHARMACEUTICAL, INC (COLL) has filed no insider reports in the last 90 days. The most recent on record is dated 10 June 2026. The full record for COLL runs to 38 Form 4 filings, the earliest from 14 November 2024. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying COLL stock?
No insider purchases of COLL were filed in the last 90 days.
How many insiders are selling COLL stock?
No insider sales of COLL were filed in the last 90 days. 18 sales are on record for this company.
Where can I see COLL SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects COLL Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Gino Santini view on EDGAR
- - John Gordon Freund view on EDGAR
- - Nancy Lurker view on EDGAR
- - Carlos V. Paya view on EDGAR
- - John Gordon Freund view on EDGAR
- - Garen G. Bohlin view on EDGAR
- - Donovan Michael Glancy view on EDGAR
- - Rita J. Balice-Gordon view on EDGAR
- - Gino Santini view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where COLL's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow COLL with a 7-day demo
- COLL on your watchlist
- Every COLL Form 4 filing on record
- Up to 3 months of COLL price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
